ProPhase Labs, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Tables)

Stockholders’ Equity (Tables)

6 Months Ended

Jun. 30, 2022

The following table summarizes stock options activity during the six months ended June 30, 2022 for the 2022 Plan, the 2022 Directors’ Plan, the 2018 Stock Plan and the Inducement Awards (in thousands, except per share data).

Schedule of Stock Options Activity

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)		Total Intrinsic Value
Outstanding as of January 1, 2022		5,110		$	3.27		3.4	$	20,820
Granted		400			6.44		7.0		-
Cashless exercised		(570	)		2.66		-		-
Forfeited		(20	)		2.87		-		-
Outstanding as of June 30, 2022		4,920		$	3.30		3.3	$	46,159
Options vested and exercisable		3,662		$	2.31		2.3	$	37,972

Summary of Weighted Average Assumptions Used in Determining Fair Value of Warrants

The following table summarizes weighted average assumptions used in determining the fair value of the options at the date of grant during the six months ended June 30, 2022 and 2021:

	For the six months ended
	June 30,
	2022			2021
Exercise price	$	6.74		$	9.13
Expected term (years)		4.8			3.5
Expected stock price volatility		77	%		83	%
Risk-free rate of interest		3.0	%		0.6	%
Expected dividend yield (per share)		0	%		0	%

Schedule of Warrant Activity

The following table summarizes warrant activity during the six months ended June 30, 2022 (in thousands, except per share data):

Schedule of Warrant Activity

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Outstanding as of January 1, 2022		855	$	8.23		1.9
Warrants granted		-		-		-
Outstanding as of June 30, 2022		855	$	8.23		1.4
Warrants vested and exercisable		855	$	8.23		1.4